Tracy Staton

Biography for Tracy Staton

Tracy Staton, Senior Editor

Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at tracy@fiercemarkets.com or find her on LinkedIn.

Articles by Tracy Staton

FDA flags particle problems in latest Hospira warning letter

Hospira's FDA woes have moved to Australia. The agency scolded the U.S.-based company in a warning letter based on an injectables plant inspection in late February and early March, according to a Wednesday securities filing.

Sunshine fact: $3.5B + 546,000 docs equals one unwieldy database

A few things are certain about the Sunshine Act data that hit the Internet Tuesday afternoon. One, it's incomplete. Two, it's controversial. Three, the numbers are pretty staggering, with $3.5 billion in payments to 546,000 doctors and 1,360 research institutions over a 5-month period.

Judge won't toss dinner-party kickback claims against Novartis

Note to sales reps: You might think twice about inviting the same doctors to the same speaker events over and over. Particularly when those events involve pricey dinners at Nobu and Smith & Wollensky.

Warning to Gilead, AbbVie and BMS: France has a new tax for pricey hep C meds

European countries are known for wresting price cuts from drugmakers. Usually, it's a straightforward cost-effectiveness argument. But France has come up with a new strategy: Arm-twisting taxes.

Gilead preps new 500-employee plant near current San Dimas site

Gilead Sciences is plotting a new, 400,000-square-foot manufacturing site near its current plant in San Dimas, CA, local media reports.

Sunshine today: The deadline for doc-payment data release arrives

Today's the day for the U.S. government to open the books on pharma payments to doctors. The Sept. 30 deadline has arrived, and the payment data mandated by the Sunshine Act will soon be public.

Salix's Relistor has its chance to get a jump on AZ's new constipation med

Salix Pharmaceuticals nabbed the new Relistor approval it was counting on. The FDA blessed the injectable drug as a treatment for all patients with constipation caused by opioid pain relievers, boosting its target market more than tenfold.

ESMO: The latest skinny on drugs from Pfizer, Novartis, GSK, Merck, BMS

The European Society for Medical Oncology meeting may not be as enormous as its U.S. counterpart, but plenty of news is flowing. And some of the new data presented in Madrid over the weekend is pretty dramatic.

Roche's Perjeta helps breast cancer patients live a record-setting 15.7 months longer

These days, even expensive cancer treatments don't necessarily deliver show-stopping study results when it comes to actually extending patients' lives. Roche's Perjeta is now a major departure from that trend.

Troubled AMAG snaps up fresh-from-bankruptcy Lumara in $1.25B deal

Troubled KV Pharmaceuticals started a new life earlier this year, emerging from bankruptcy and changing its name to Lumara Health. Now, it's selling out. AMAG Pharmaceuticals agreed to pay up to $1.25 billion for the company's maternal health business and its once-controversial preterm-labor treatment Makena.